| Name | Title | Contact Details |
|---|
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
Live instruction, homework and personalized feedback from TAs, study groups, community features and real outcomes for top performers help us create a more interactive and social remote learning experience....
KLDiscovery provides technology-enabled services and software to help law firms, corporations, government agencies and consumers solve complex data challenges.
Shieldpay provides simple and transparent payment solutions across the legal, financial and professional services industries.
Zwift is an interactive fitness entertainment platform that brings the excitement and camaraderie of outdoor cycling indoors. It transforms monotonous solo indoor cycling workouts into dynamic and social adventures that entertain and motivate.